SASB Blog

Filters

Governance Transition FAQs

Governance Transition FAQs
February 15, 2017

What governance transition is SASB undergoing? SASB is transitioning to a two-tiered governance model with separation of financial responsibilities from the standards-setting […]

Read more

Despite Headline Risks, Disclosure on Drug Pricing Remains Limited for Pharmaceuticals Companies

Despite Headline Risks, Disclosure on Drug Pricing Remains Limited for Pharmaceuticals Companies
February 13, 2017

How and why SASB is working towards enhanced disclosure on pricing strategies. In 2016, drug pricing emerged as a headline risk for […]

Read more

Moving from Provisional to Codified: An Update on the Consultation Period

Moving from Provisional to Codified: An Update on the Consultation Period
February 6, 2017

SASB’s deep consultation process on the Provisional Standards and proposed updates is going “full speed ahead.” We invite corporate issuers and investors […]

Read more

A Letter from Jean Rogers, SASB’s CEO

A Letter from Jean Rogers, SASB’s CEO
April 6, 2016

Dear SASB Stakeholders, Four years ago, SASB embarked upon an ambitious task. We promised the markets that by March 2016 we would […]

Read more

Sustainability and the Five Forces Model